Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2023-12-12 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
华英证券有限责任公司关于深圳信立泰药业股份有限公司变更部分募投项目实施主体、实施方式及原实施主体减资的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report from a sponsoring securities company regarding changes in the implementation subject and method of certain fundraising investment projects by Shenzhen Salubris Pharmaceuticals Co., Ltd. It includes specifics about the fundraising amount, usage, project changes, board and supervisory approvals, and audit confirmations. The content focuses on the use and management of raised funds, project implementation changes, and related corporate governance procedures. It is not a full annual or interim financial report, nor is it a simple announcement or certification. The document is comprehensive and contains substantive financial and operational details related to capital use and project management, fitting the category of a Capital/Financing Update (CAP).
2023-12-12 Chinese
《公司章程》修正案
Governance Information Classification · 95% confidence The document is a detailed amendment to the company's Articles of Association (公司章程) including changes to board procedures, director nomination, resignation, and profit distribution policies. It references legal and regulatory frameworks but does not contain financial statements or results. It is a governance-related document focusing on internal company rules and board responsibilities. The document length is 4426 characters, which is relatively short but contains substantive content rather than just an announcement. Therefore, it is not a report publication announcement or a regulatory filing. The content fits the definition of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2023-12-12 Chinese
关于调整部分募投项目内部投资结构并延期的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the adjustment of internal investment structure and extension of certain fundraising projects by Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the use of funds raised from a non-public stock issuance, adjustments to clinical research projects, and the approval process involving the board of directors, supervisory board, independent directors, and the sponsor institution. The document does not contain comprehensive financial statements or detailed financial performance data typical of an Annual Report or Interim Report. It is not a call transcript, earnings release, or a regulatory certification. Instead, it is a formal announcement about changes related to capital raised and its usage, including project delays and internal investment adjustments. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document length is 4740 characters, sufficient to provide substantive information rather than a mere announcement of a report publication. Therefore, the best classification is CAP with high confidence.
2023-12-12 Chinese
华英证券有限责任公司关于深圳信立泰药业股份有限公司调整部分募投项目内部投资结构并延期的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from a sponsoring securities company regarding the adjustment of internal investment structure and extension of certain fundraising projects by Shenzhen Salubris Pharmaceuticals Co., Ltd. It includes specifics about the fundraising amount, usage, project adjustments, board and supervisory approvals, and compliance with regulatory guidelines. The content focuses on the management and use of raised funds, project progress, and related approvals, which aligns with a Capital/Financing Update. It is not a full annual or interim report, audit report, or earnings release, nor is it a simple announcement or certification. The document length (4517 characters) and detailed financial and project data support classification as a Capital/Financing Update (CAP).
2023-12-12 Chinese
董事会提名委员会工作细则（2023年12月）
Governance Information Classification · 95% confidence The document is titled '董事会提名委员会工作细则' which translates to 'Board Nomination Committee Working Rules'. It details the structure, responsibilities, procedures, and rules governing the nomination committee of the board of directors. It includes sections on composition, duties, decision-making processes, meeting rules, confidentiality, and implementation. There is no financial data, no mention of annual or quarterly results, no voting results, no legal proceedings, no capital changes, no executive compensation, and no investor presentation content. The document is a governance-related internal rules document about board nomination committee operations, which fits the definition of Governance Information (CGR). The document length is 3145 characters, which is consistent with a detailed governance policy document rather than a brief announcement or a full annual report.
2023-12-12 Chinese
董事会议事规则（2023年12月）
Governance Information Classification · 100% confidence The document is titled '董事会议事规则' which translates to 'Rules of Procedure for the Board of Directors'. It details the internal rules, decision-making processes, powers, meeting procedures, voting, and responsibilities of the board of directors of Shenzhen Salubris Pharmaceuticals Co., Ltd. It references company law, company articles, and governance structures. There is no financial data, audit results, or report publication mentioned. The content is focused on governance practices and board management. Therefore, this document fits the category of Governance Information (CGR). The document length is sufficient and it is not an announcement or a brief notice, but a full set of governance rules.
2023-12-12 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.